FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person * Young Richard A				2. Issuer Name and Ticker or Trading Symbol Syros Pharmaceuticals, Inc. [SYRS]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
(Last) (First) (Middle) C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, SUITE 300				3. Date of Earliest Transaction (Month/Day/Year) 08/15/2019					Office	er (give title belo	ow)	Other (specify	pelow)		
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person						
CAMBRIDGE, MA 02139 (City) (State) (Zip)				Т	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yo		Date	2A. Deemed Execution Date, any	(Instr. 8)		ction	tion 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		of (D)			Ownership of Form:	7. Nature of Indirect Beneficial Ownership		
			(Month/Day/Yea		ode	v	Amoun	(A) or (D)	Price	(IIIsti. 3 a	and 4)			(Instr. 4)	
Common Stock			08/15/2019		S	(1)		2,300	D	\$ 10	417,801		D		
Common Stock 08/16/2019		08/16/2019		S	(1)		22,700) D	\$ 10	395,101		D			
Reminder:	Report on a	separate line for		Derivative Securi	ties Ac	equire	Pers cont the f	ons wh ained ir orm dis	o respon this for plays a	rm are curre reficial	not requesting ntly valid	OMB con	formation spond unle trol numbe	ess	1474 (9-02)
1. Title of	2	3. Transaction		e.g., puts, calls, v	varran 5	ts, opt		, convert ate Exerc			itle and	8. Price of	9. Number	of 10.	11. Natur
		version Date (Month/Day/Year) Execution Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)		Transaction Number of		and Expiration Date (Month/Day/Year) S (I		Ame Und Secu	nount of derlying curities str. 3 and		Derivative (Securities Beneficially Owned Sollowing Reported Transaction(s)	Owners Form of Derivat Security Direct (or Indir	hip of Indirect Beneficia Ownershi (Instr. 4) D)		
				Code V	(A)	(D)	Date Exer		Expiration Date	n Title	Amount or Number of Shares				

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Young Richard A C/O SYROS PHARMACEUTICALS, INC. 620 MEMORIAL DRIVE, SUITE 300 CAMBRIDGE, MA 02139	X					

Signatures

/s/ Gerald E. Quirk, as attorney-in-fact	08/19/2019

**Signature of Reporting Person	Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.